A decade on, the German pharma giant is worth less than the $62 bln it paid for Roundup's maker. Known legal risks ...
Bayer used illegal and anti-competitive practices to monopolize the U.S. market for genetically engineered corn seeds, reaping "hundreds of millions, if not billions, of ill-gotten dollars," ...
Not only do golf's majors bring together the biggest names in the sport, they also afford lesser-known but still talented players the opportunity to tee it up alongside the superstars. The Masters, ...
WINNIPEG — Bayer wants farmers to grow more camelina, an oilseed crop that resembles canola. On May 6, Bayer and BP announced what they’re calling a “strategic alliance” to increase production of ...
Bayer BAYN0.55%increase; green up pointing triangle said it agreed to buy Perfuse Therapeutics for up to $2.45 billion, snapping up an eye-drug specialist that is developing a potential glaucoma ...
Bayer AG agreed to buy eye-medicines maker Perfuse Therapeutics Inc. as it looks to strengthen its pipeline amid rising generic competition for some of its blockbuster drugs. The deal could be worth ...
Bayer has agreed terms for its first biopharma acquisition in years, paying $300 million upfront for privately-held US biotech Perfuse Therapeutic and its novel drug implant for eye diseases. The deal ...
Bayer has agreed to acquire biotechnology startup Perfuse Therapeutics in a deal that could be worth up to $2.45 billion, marking the healthcare conglomerate’s first — and potentially largest — drug ...
WASHINGTON - The U.S. Supreme Court appeared divided over Bayer AG's effort to shut down thousands of lawsuits accusing the company of failing to warn users that the active ingredient in its Roundup ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results